Comprehensive assessment of nephrotoxicity of intravenously administered sodium-oleate-coated ultra-small superparamagnetic iron oxide (USPIO) and titanium dioxide (TiO2) nanoparticles in rats

Nanotoxicology

Volumn 8, Issue 2, 2014, Pages 142-157

  Šebeková, Katarína ^a   Dušinská, Mária ^b   Simon Klenovics, Kristína ^a   Kollárová, Radana ^a   Boor, Peter ^a,c   Kebis, Anton ^d   Staruchová, Marta ^d   Vlková, Barbora ^a   Celec, Peter ^a   Hodosy, Július ^a   Bačiak, Ladislav ^e   Tušková, Radka ^e   Beňo, Milan ^d   Tulinská, Jana ^d   Príbojová, Jana ^d   Bilaničová, Dagmar ^f   Pojana, Giulio ^f   Marcomini, Antonio ^f   Volkovová, Katarína ^d  

^a Physics and Informatics   (Slovakia)

^b NORWEGIAN INSTITUTE FOR AIR RESEARCH   (Norway)

^c RWTH AACHEN UNIVERSITY   (Germany)

^d SLOVAK MEDICAL UNIVERSITY   (Slovakia)

^e SLOVAK UNIVERSITY OF TECHNOLOGY   (Slovakia)

^f CA' FOSCARI UNIVERSITY OF VENICE   (Italy)

Author keywords

Gene expression; Micro inflammation; Nanoparticles; Oxidative stress; Renal function; Renal histology

Indexed keywords

NANOPARTICLE; OLEATE SODIUM; TITANIUM DIOXIDE; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOAVAILABILITY; COMPUTER MODEL; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; GENE EXPRESSION; HISTOLOGY; IN VITRO STUDY; KIDNEY CORTEX; KIDNEY FUNCTION; KIDNEY PROXIMAL TUBULE; NEPHROTOXICITY; NONHUMAN; ORAL DRUG ADMINISTRATION; OXIDATIVE STRESS; PREDICTION; PRIORITY JOURNAL; RAT; RISK ASSESSMENT;

ANIMALS; FEMALE; FIBROSIS; INFLAMMATION; KIDNEY; KIDNEY DISEASES; LETHAL DOSE 50; MAGNETIC RESONANCE SPECTROSCOPY; MAGNETITE NANOPARTICLES; METAL NANOPARTICLES; OLEIC ACID; OXIDATIVE STRESS; RATS; RATS, WISTAR; TITANIUM; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84890390346     PISSN: 17435390     EISSN: 17435404     Source Type: Journal    
DOI: 10.3109/17435390.2012.763147     Document Type: Article

References (93)

1. Agarwal R, Vasavada N, Sachs NG, Chase S. 2004. Oxidative stress and renal injury with intravenous iron in patients with chronic kidney disease. Kidney Int 65:2279-2289
2. Aurelie NDC, Touyz RM. 2011. A new look at the renin-Angiotensin system-focusing on the vascular system. Peptides 32:2141-2150
3. Bailey M, Christoforidou Z, Lewis MC. 2012. The evolutionary basis for differences between the immune systems of man, mouse, pig and ruminants. Vet Immunol Immunopathol http://dx.doi.org/10.1016/ j.vetimm.2012.09.022
4. Benzie IF, Strain JJ. 1996. The ferric reducing ability of plasma (FRAP) as a measure of antioxidant power: The FRAP assay. Anal Biochem 239:70-76
5. Bierhaus A, Humpert PM, Morcos M, Wendt T, Chavakis T, Arnold B, et al. 2005. Understanding RAGE, the receptor for advanced glycation end products. J Mol Med (Berl) 83:876-886
6. Bishu K, Agarwal R. 2006. Acute injury with intravenous iron and concerns regarding long-Term safety. Clin J Am Soc Nephrol 1(Suppl 1):S19-S23
7. Boger RH. 2005. Asymmetric dimethylarginine (ADMA) and cardiovascular disease: Insights from prospective clinical trials. Vasc Med 10(Suppl 1):S19-S25
8. Boor P, Casper S, Celec P, Hurbankova M, Beno M, Heidland A, et al. 2009. Renal, vascular and cardiac fibrosis in rats exposed to passive smoking and industrial dust fibre amosite. J Cell Mol Med 13:4484-4491
9. Boor P, Konieczny A, Villa L, Kunter U, van Roeyen CR, LaRochelle WJ, et al. 2007. PDGF-D inhibition by CR002 ameliorates tubulointerstitial fibrosis following experimental glomerulonephritis. Nephrol Dial Transplant 22:1323-1331
10. Boor P, Celec P, Martin IV, Villa L, Hodosy J, Klenovicsová K, et al. 2011. The peroxisome proliferator-Activated receptor-Alpha agonist, BAY PP1, attenuates renal fibrosis in rats. Kidney Int 80:1182-1197
11. Bradford MM. 1976. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254
12. Brownlee M. 1995. Advanced protein glycosylation in diabetes and aging. Annu Rev Med 46:223-234
13. Carello KA, Whitesall SE, Lloyd MC, Billecke SS, D'Alecy LG. 2006. Asymmetrical dimethylarginine plasma clearance persists after acute total nephrectomy in rats. Am J Physiol Heart Circ Physiol 290:H209-H216
14. Cavarocchi NC, England MD, O'Brien JF, Solis E, Russo P, Schaff HV, et al. 1986. Superoxide generation during cardiopulmonary bypass: Is there a role for vitamin E? J Surg Res 40:519-527
15. Celec P, Hodosy J, BehuliakM, Palffy R, Gardlik R, Halcak L, et al. 2012. Oxidative and carbonyl stress in patients with obstructive sleep apnea treated with continuous positive airway pressure. Sleep Breath 16:393-398
16. Chen SX, Song T, Zhou SH, Liu YH, Wu SJ, Liu LY. 2008. Protective effects of ACE inhibitors on vascular endothelial dysfunction induced by exogenous advanced oxidation protein products in rats. Eur J Pharmacol 584:368-375
17. Crawford RM, Leiby DA, Green SJ, Nacy CA, Fortier AH, Meltzer MS. 1994. Macrophage activation: A riddle of immunological resistance. Immunol Ser 60:29-46
18. Cruz DN, Fard A, Clementi A, Ronco C, Maisel A. 2012. Role of biomarkers in the diagnosis and management of cardio-renal syndromes. Semin Nephrol 32:79-92
19. De Jong WH, Van Loveren H. 2007. Screening of xenobiotics for direct immunotoxicity in an animal study. Methods 41:3-8
20. De Vecchi AF, Bamonti F, Novembrino C, Ippolito S, Guerra L, Lonati S, et al. 2009. Free and total plasma malondialdehyde in chronic renal insufficiency and in dialysis patients. Nephrol Dial Transplant 24:2524-2529
21. Duguet E, Vasseur S, Mornet S, Devoisselle JM. 2006. Magnetic nanoparticles and their applications in medicine. Nanomedicine 1:157-168
22. Dusinska M, Fjellsbø L, Magdolenova Z, Rinna A, Runden Pran E, Bartonova A, et al. 2009. Testing strategies for the safety of nanoparticles used in medical applications. Nanomedicine (Lond) 4:605-607
23. Fabian E, Landsiedel R, Ma-Hock L, Wiench K, Wohlleben W, van Ravenzwaay B. 2008. Tissue distribution and toxicity of intravenously administered titanium dioxide nanoparticles in rats. Arch Toxicol 82:151-157
24. Fadda LM, Abdel Baky NA, Al-Rasheed NM, Al-Rasheed NM, Fatani AJ, Atteya M. 2012. Role of quercetin and arginine in ameliorating nano zinc oxide-induced nephrotoxicity in rats. BCM Complement Altern Med 12:60e
25. Feng J, Liu H, Zhang L, Bhakoo K, Lu L. 2010. An insight into the metabolic responses of ultra-small superparamagnetic particles of iron oxide using metabonomic analysis of biofluids. Nanotechnology 21:395101
26. Feng J, Liu H, Bhakoo KK, Lu L, Chen Z. 2011. A metabonomic analysis of organ specific response to USPIO administration. Biomaterials 32:6558-6569
27. Fliser D. 2005. Asymmetric dimethylarginine (ADMA): The silent transition from an 'uraemic toxin' to a global cardiovascular risk molecule. Eur J Clin Invest 35:71-79
28. Guo ZJ, Niu HX, Hou FF, Zhang L, Fu N, Nagai R, et al. 2008. Advanced oxidation protein products activate vascular endothelial cells via a RAGE-mediated signaling pathway. Antioxid Redox Signal 10:1699-1712
29. Habig WH, Pabst MJ, Jakoby WB. 1974. Glutathione S-Transferases. The first enzymatic step in mercapturic acid formation. J Biol Chem 249:7130-7139
30. Han WK, Bailly V, Abichandani R, Thadhani R, Bonventre JV. 2002. Kidney Injury Molecule-1 (KIM-1): A novel biomarker for human renal proximal tubule injury. Kidney Int 62:237-244
31. Holsapple MP, Farland WH, Landry TD, Monteiro-Riviere NA, Carter JM, Walker NJ, et al. 2005. Research strategies for safety evaluation of nanomaterials, part II: Toxicological and safety evaluation of nanomaterials, current challenges and data needs. Toxicol Sci 88:12-17
32. Huo W, Zhang K, Nie Z, Li Q, Jin F. 2010. Kidney injury molecule-1 (KIM-1): A novel kidney-specific injury molecule playing potential double-edged functions in kidney injury. Transplant Rev (Orlando) 24:143-146
33. Ichimura T, Bonventre JV, Bailly V, Wei H, Hession CA, Cate RL, et al. 1998. Kidney injury molecule-1 (KIM-1), a putative epithelial cell adhesion molecule containing a novel immunoglobulin domain, is up-regulated in renal cells after injury. J Biol Chem 273:4135-4142
34. Islam T, Wolf G. 2009. The pharmacokinetics of the lymphotropic nanoparticle MRI contrast agent ferumoxtran-10. Cancer Biomark 5:69-73
35. Ismagilov ZR, Tsykoza LT, Shikina NV, Zarytova VF, Zinoviev VV, Zagrebelnyi SN. 2009. Synthesis and stabilization of nano-sized titanium dioxide. Russian Chem Rev 78:873-885
36. Jain TK, Reddy MK, Morales MA, Leslie-Pelecky DL, Labhasetwar V. 2008. Biodistribution, clearance, and biocompatibility of iron oxide magnetic nanoparticles in rats. Mol Pharm 5:316-327
37. Kenzaoui BH, Bernasconi CC, Guney-Ayra S, Juillerat-Jeanneret L. 2012. Induction of oxidative stress, lysosome activation and autophagy by nanoparticles in human brain-derived endothelial cells. Biochem J 441:813-821
38. Kim JE, Shin JY, Cho MH. 2012. Magnetic nanoparticles: An update of application for drug delivery and possible toxic effects. Arch Toxicol 86:685-700
39. Kir HM, Dillioglugil MO, Tugay M, Eraldemir C, Ozdogan HK. 2005. Effects of vitamins E, A and D on MDA, GSH, NO levels and SOD activities in 5/6 nephrectomized rats. Am J Nephrol 25:441-446
40. Koomans HA, Blankestijn PJ, Joles JA. 2004. Sympathetic hyperactivity in chronic renal failure: A wake-up call. J Am Soc Nephrol 15:524-537
41. Koska J, Syrova D, Blazicek P, Marko M, Grna JD, Kvetnansky R, et al. 1999. Malondialdehyde, lipofuscin and activity of antioxidant enzymes during physical exercise in patients with essential hypertension. J Hypertens 17:529-535
42. Kudo H, Suzuki S, Watanabe A, Kikuchi H, Sassa S, Sakamoto S. 2008. Effects of colloidal iron overload on renal and hepatic siderosis and the femur in male rats. Toxicology 246:143-147
43. Laniado M, Chachuat A. 1995. The endorem tolerance profile. Radiologe 35:S266-S270
44. Lei RH, Wu CQ, Yang BH, Ma HZ, Shi C, Wang QJ, et al. 2008. Integrated metabolomic analysis of the nano-sized copper particle-induced hepatotoxicity and nephrotoxicity in rats: A rapid in vivo screening method for nanotoxicity. Toxicol Appl Pharmacol 232:292-301
45. Li HY, Hou FF, Zhang X, Chen PY, Liu SX, Feng JX, et al. 2007. Advanced oxidation protein products accelerate renal fibrosis in a remnant kidney model. J Am Soc Nephrol 18:528-538
46. Liao MY, Liu HG. 2012. Gene expression profiling of nephrotoxicity from copper nanoparticles in rats after repeated oral administration. Environ Toxicol Pharmacol 34:67-80
47. Lim CS, Vaziri ND. 2004. Iron and oxidative stress in renal insufficiency. Am J Nephrol 24:569-575
48. Magdolenova Z, Rinna A, Fjellsbo L, Dusinska M. 2011. Safety assessment of nanoparticles cytotoxicity and genotoxicity of metal manoparticles in vitro. J Biomed Nanotechnol 7:20-21
49. Majewski P, Thierry B. 2007. Functionalized magnetite nanoparticles-synthesis, properties, and bio-Applications. Crit Rev Solid State Mater Sci 32:203-215
50. Marsche G, Frank S, Hrzenjak A, Holzer M, Dirnberger S, Wadsack C, et al. 2009. Plasma-Advanced oxidation protein products are potent high-density lipoprotein receptor antagonists in vivo. Circ Res 104:750-757
51. Matsuyama Y, Terawaki H, Terada T, Era S. 2009. Albumin thiol oxidation and serum protein carbonyl formation are progressively enhanced with advancing stages of chronic kidney disease. Clin Exp Nephrol 13:308-315
52. Mestas J, Hughes CCW. 2004. Of mice and not men: Differences between mouse and human immunology. J Immunol 172:2731-2738
53. Mishra OP, Pooniya V, Ali Z, Upadhyay RS, Prasad R. 2008. Antioxidant status of children with acute renal failure. Pediatr Nephrol 23:2047-2051
54. Miyata T, Kurokawa K, van Ypersele de Strihou C. 2000. Relevance of oxidative and carbonyl stress to long-Term uremic complications. Kidney Int Suppl 76:S120-S125
55. Munch G, Keis R, Wessels A, Riederer P, Bahner U, Heidland A, et al. 1997. Determination of advanced glycation end products in serum by fluorescence spectroscopy and competitive ELISA. Eur J Clin Chem Clin Biochem 35:669-677
56. Oberdorster G. 2010. Safety assessment for nanotechnology and nanomedicine: Concepts of nanotoxicology. J Intern Med 267:89-105
57. OECD. 2000. Guidance Document on Acute Oral Toxicity. Environmental Health and Safety Monograph Series on Testing and Assessment No. 24
58. Ohtani B, Prieto-Mahaney OO, Li D, Abe R. 2010. What is Degussa (Evonik) P25? Crystalline composition analysis, reconstruction from isolated pure particles and photocatalytic activity test. J Photochem Photobiol A-Chem 216:179-182
59. Padma VV, Baskaran R, Roopesh RS, Poornima P. 2012. Quercetin attenuates lindane induced oxidative stress in wistar rats. Mol Biol Rep 39:6895-6905
60. Paglia DE, Valentine WN. 1967. Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase. J Lab Clin Med 70:158-169
61. Pándics T. 2008. Clinical application of nanoparticles, and their possible health risk. Orv Hetil 149:1785-1790
62. Park JH, Kim S, Bard AJ. 2006. Novel carbon-doped TiO2 nanotube arrays with high aspect ratios for efficient solar water splitting. Nano Lett 6:24-28
63. Pfaller T, Colognato R, Nelissen I, Favilli F, Casals E, Ooms D, et al. 2010. The suitability of different cellular in vitro immunotoxicity and genotoxicity methods for the analysis of nanoparticle-induced events. Nanotoxicology 4:52-72
64. Poirier B, Lannaud-Bournoville M, Conti M, Bazin R, Michel O, Bariety J, et al. 2000. Oxidative stress occurs in absence of hyperglycaemia and inflammation in the onset of kidney lesions in normotensive obese rats. Nephrol Dial Transplant 15:467-476
65. Pujalte I, Passagne I, Brouillaud B, Treguer M, Durand E, Ohayon-Courtes C, et al. 2011. Cytotoxicity and oxidative stress induced by different metallic nanoparticles on human kidney cells. Part Fibre Toxicol 8:10
66. Rosner MH, Ronco C, Okusa MD. 2012. The role of inflammation in the cardio-renal syndrome: A focus on cytokines and inflammatory mediators. Semin Nephrol 32:70-78
67. Santmyire BR, Venkat V, Beinder E, Baylis C. 2010. Impact of the estrus cycle and reduction in estrogen levels with aromatase inhibition, on renal function and nitric oxide activity in female rats. Steroids 75:1011-1015
68. Sebekova K, Blazicek P, Syrova D, Krivosikova Z, Spustova V, Heidland A, et al. 2001. Circulating advanced glycation end product levels in rats rapidly increase with acute renal failure. Kidney Int Suppl 78:S58-S62
69. Shimizu MH, Araujo M, Borges SM, de Tolosa EM, Seguro AC. 2004. Influence of age and vitamin E on post-ischemic acute renal failure. Exp Gerontol 39:825-830
70. Schinzel R, Munch G, Heidland A, Sebekova K. 2001. Advanced glycation end products in end-stage renal disease and their removal. Nephron 87:295-303
71. Singbartl K. 2011. Renal-pulmonary crosstalk. In: Kellum JA, Ronco C, Vincent JL, editors. Controversies in acute kidney injury. Basel: Karger. Vol. 174. pp 65-70
72. Star RA. 1998. Treatment of acute renal failure. Kidney Int 54:1817-1831
73. Stern ST, McNeil SE. 2008. Nanotechnology safety concerns revisited. Toxicol Sci 101:4-21
74. Sun J, Zhou S, Hou P, Yang Y, Weng J, Li X, et al. 2007. Synthesis and characterization of biocompatible Fe3O4 nanoparticles. J Biomed Mater Res A 80:333-341
75. Šebeková K Jr, Bla-zíček P, Syrová D, Galbavý Š, Schinzel R, Heidland A, et al. 2010. Oxidative stress, advanced glycation end products and residual renal function in the rat model of unilateral ureteral obstruction: Effects of phlogenzym and losartan. Biopolymers Cell 26:121-127
76. Terrier-Lenglet A, Nollet A, Liabeuf S, Barreto DV, Brazier M, Lemke HD, et al. 2011. Plasma malondialdehyde may not predict mortality in patient with chronic kidney disease. Nephrol Ther 7:219-224
77. Tetley TD. 2007. Health effects of nanomaterials. Biochem Soc Trans 35:527-531
78. Thomas MC. 2011. Advanced glycation end products. In: Lai KN, Tang SCW, editors. Diabetes and the kidney. Vol. 170. pp 66-74
79. Thornalley PJ, Rabbani N. 2009. Highlights and hotspots of protein glycation in end-stage renal disease. Semin Dial 22:400-404
80. Vaidya VS, Ozer JS, Dieterle F, Collings FB, Ramirez V, Troth S, et al. 2010. Kidney injury molecule-1 outperforms traditional biomarkers of kidney injury in preclinical biomarker qualification studies. Nat Biotechnol 28:478-485
81. Van Loveren H, De Jong WH, Vandebriel RJ, Vos JG, Garssen J. 1998. Risk assessment and immunotoxicology. Toxicol Lett 103:261-265
82. van Ravenzwaay B, Landsiedel R, Fabian E, Burkhardt S, Strauss V, Ma-Hock L. 2009. Comparing fate and effects of three particles of different surface properties: Nano-TiO(2), pigmentary TiO(2) and quartz. Toxicol Lett 186:152-159
83. van Timmeren MM, van den Heuvel MC, Bailly V, Bakker SJ, van Goor H, Stegeman CA. 2007. Tubular kidney injury molecule-1 (KIM-1) in human renal disease. J Pathol 212:209-217
84. Vanholder R, De Smet R, Glorieux G, Argilés A, Baurmeister U, Brunet P, et al. 2003. Review on uremic toxins: Classification, concentration, and interindividual variability. Kidney Int 63:1934-1943
85. Volkovova K, Beno M, Tulinska J, Handy R, Dusinska M. 2013. Median lethal dose of titanium dioxide and Na-oleate coated iron oxide nanoparticles after single intravenous injection to adult rats. Acute toxicity study. Nanotoxicology; in Press
86. Wang J, Chen Y, Chen B, Ding J, Xia G, Gao C, et al. 2010. Pharmacokinetic parameters and tissue distribution of magnetic Fe(3)O(4) nanoparticles in mice. Int J Nanomedicine 5:861-866
87. Wang JX, Zhou G, Chen C, Yu H, Wang T, Ma Y, et al. 2007. Acute toxicity and biodistribution of different sized titanium dioxide particles in mice after oral administration. Toxicol Lett 168:176-185
88. Weingand K, Brown G, Hall R, Davies D, Gossett K, Neptun D, et al. 1996. Harmonization of animal clinical pathology testing in toxicity and safety studies. Fundam Appl Toxicol 29:198-201
89. Witko-Sarsat V, Friedlander M, Capeillere-Blandin C, Nguyen-Khoa T, Nguyen AT, Zingraff J, et al. 1996. Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int 49:1304-1313
90. Wong SH, Knight JA, Hopfer SM, Zaharia O, Leach CN Jr, Sunderman FW Jr. 1987. Lipoperoxides in plasma as measured by liquid-chromatographic separation of malondialdehyde-Thiobarbituric acid adduct. Clin Chem 33:214-220
91. Yan GY, Huang Y, Bu Q, Lv L, Deng P, Zhou J, et al. 2012. Zinc oxide nanoparticles cause nephrotoxicity and kidney metabolism alterations in rats. J Environ Sci Health A Tox Hazard Subst Environ Eng 47:577-588
92. Zager RA. 2005. Parenteral iron treatment induces MCP-1 accumulation in plasma, normal kidneys, and in experimental nephropathy. Kidney Int 68:1533-1542
93. Zhang R, Niu YJ, Li YW, Zhao CF, Song B, Li Y, et al. 2010. Acute toxicity study of the interaction between titanium dioxide nanoparticles and lead acetate in mice. Environ Toxicol Pharmacol 30:52-60